Navigation Links
Catalent Pharma Solutions, Inc. Announces Increase In Tender Cap For Its Cash Tender Offer For Its 9-1/2%/10-1/4% Senior PIK-Election Notes Due 2015
Date:9/5/2012

SOMERSET, N.J., Sept. 5, 2012 /PRNewswire/ -- Catalent Pharma Solutions, Inc. ("Catalent") announced today that it has increased the principal amount of its outstanding 9-1/2%/10-1/4% Senior PIK-Election Notes due 2015 (the "Notes") offered to be repurchased pursuant to its previously announced offer to purchase (the "Offer") from $250 million to $350 million (as amended, the "Tender Cap").  

Except as set forth above, the terms and conditions of the Offer described in the Offer to Purchase, dated September 4, 2012 (the "Offer to Purchase"), and the related Letter of Transmittal (the "Letter of Transmittal") remain unchanged. 

The following table identifies the Notes to which the Offer relates, Tender Offer Consideration, Early Tender Payment and Total Consideration (each as defined below) offered pursuant to the Offer.  The Tender Offer Consideration will equal the Total Consideration less the Early Tender Payment set forth in the table below.Title of SecuritiesCUSIP NumberAggregate Principal Amount OutstandingTender Offer Consideration(1)Early Tender Payment(1)Total Consideration(1)(2)9-1/2/10-1/4% Senior PIK-Election Notes due 2015

14150BAC8

$619,133,490

$1,000.00

$27.50

$1,027.50(1) Per $1,000 principal amount of Notes tendered and accepted for purchase. (2) Inclusive of the Early Tender Payment.The Offer will expire at 11:59 p.m., New York City time, on October 1, 2012 unless extended by Catalent (such time and date, as may be extended, the "Expiration Date").  Holders of Notes that validly tender and do not validly withdraw their Notes in the Offer at or prior to 5:00 p.m., New York City time, on September 17, 2012 (the "Early Tender Date"), and whose Notes are accepted for purchase by Catalent will be entitled to receive the total consideration of $1,027.50 per $1,000 principal amount of Notes tendered and accepted for purchase (the "Total Consideration"), which includes the early tender payment of $27.50 per $1,000 principal amount of Notes tendered and accepted for purchase (the "Early Tender Payment").  Holders of Notes that are tendered in the Offer after the Early Tender Date but at or prior to the Expiration Date and are accepted for purchase by Catalent will receive in respect of their Notes purchased the tender offer consideration of $1,000.00 per $1,000 principal amount of such Notes (the "Tender Offer Consideration"), which is equal to the Total Consideration less the Early Tender Payment.  In addition, holders of Notes accepted for purchase will receive payment of accrued and unpaid interest on their purchased Notes from the last interest payment date applicable to such Notes to, but not including, the applicable date of payment for such Notes ("Accrued Interest").

Catalent may accept for purchase on a business day after the Early Tender Date and prior to the Final Settlement Date (as defined below), subject to the satisfaction or waiver of the conditions to the Offer, a portion of the Notes that are validly tendered and not validly withdrawn at or prior to the Early Tender Date.  Because Catalent is offering to purchase only a portion of the Notes outstanding, on any Early Settlement Date Catalent expects to accept for purchase and pay for a principal amount of Notes equal to (i) the principal amount of Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date multiplied by (ii) the "Early Acceptance Factor," which will equal the fraction, (a) the numerator of which will be equal to the Tender Cap and (b) the denominator of which will be equal to the principal amount of Notes outstanding at the commencement of the Offer, subject to the proration procedures described in the Offer to Purchase.  Catalent may elect not to exercise its early acceptance right, in which event any Notes to be purchased pursuant to the Offer will be purchased on the Final Settlement Date.  With respect to any Notes accepted for purchase prior to the Final Settlement Date, payment of the Total Consideration for such Notes accepted for purchase will be made on such date by Catalent's deposit with The Depository Trust Company ("DTC") of the aggregate Total Consideration for Notes accepted for purchase on such date, together with an amount equal to Accrued Interest.  Any date on which early acceptance for purchase and settlement occurs is referred to herein as the "Early Settlement Date." 

Subject to the terms and conditions set forth herein (including the Tender Cap and the application of the proration procedures described in the Offer to Purchase) and in the Letter of Transmittal, promptly following the Expiration Date Catalent intends to accept for purchase and pay for a principal amount of Notes equal to (i) the Notes validly tendered and not validly withdrawn pursuant to the Offer that remain unpurchased following any Early Settlement Date, multiplied by (ii) the "Final Acceptance Factor," which will equal the fraction, (a) the numerator of which will be equal to the Tender Cap less the principal amount of Notes purchased on any Early Settlement Date and (b) the denominator of which will be equal to the total principal amount of Notes tendered in the Offer and not purchased on any Early Settlement Date, subject to the proration procedures described in the Offer to Purchase.  On such date Catalent will deposit with DTC the aggregate amount of funds required to purchase Notes accepted on such date, together with an amount equal to the applicable Accrued Interest.  Any date on which final acceptance for purchase and settlement occurs is referred to herein as the "Final Settlement Date." 

Notwithstanding any other provision of the Offer, Catalent's obligation to accept for purchase and to pay for Notes that are validly tendered and not validly withdrawn pursuant to the Offer is subject to the Tender Cap.  If Notes are validly tendered and not validly withdrawn such that the principal amount tendered exceeds the Tender Cap, Catalent may decline to accept for purchase Notes in an aggregate principal amount exceeding the Tender Cap. 

The obligation of Catalent to accept for purchase and pay for Notes validly tendered pursuant to the Offer is conditioned on satisfaction or waiver of a number of conditions set forth in the Offer to Purchase, including the financing condition described in the Offer to Purchase.  The Offer is not conditioned upon any minimum principal amount of Notes being tendered.

Holders may withdraw Notes validly tendered at any time prior to 5:00 p.m., New York City time on September 17, 2012 but, except as provided in the Offer to Purchase or required by law, after such time Notes may not be validly withdrawn.  Notes validly withdrawn may be retendered at any time at or prior to the Expiration Date.

Morgan Stanley & Co. LLC is the Dealer Manager for the Offer.  Questions regarding the Offer may be directed to them at 1 (800) 624-1808 (toll free) or 1 (212) 761-1057 (direct).  D.F. King & Co., Inc. has been retained as tender agent and information agent for the Offer.  Requests for documents may be directed to D. F. King & Co., Inc. by telephone at 1 (800) 290-6427 (toll free) or in writing at 48 Wall Street, 22nd Floor, New York, New York  10005, Attention:  Elton Bagley.  Catalent is making the Offer only by, and pursuant to the terms and conditions set forth in, the Offer to Purchase and the related Letter of Transmittal, each as amended hereby.  Holders are encouraged to read all of the documents relating to the Offer carefully before taking action with respect to the Offer.

This news release shall not constitute an offer to sell, a solicitation to buy or an offer to purchase or sell any securities.  No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful.


'/>"/>
SOURCE Catalent Pharma Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalent Pharma Solutions, Inc. Announces Cash Tender Offer for up to $250 Million of Its 9-1/2%/10-1/4% Senior PIK-Election Notes due 2015
2. Frazier Healthcare Acquires U.S. Commercial Pharmaceutical Packaging Operations from Catalent Pharma Solutions
3. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
4. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
5. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
6. Questcor Pharmaceuticals to Present at Investor Conferences in September
7. Eaton Scientific Enters Agreement with RoxSan Pharmacy to Provide Tropine 3 for its upcoming Clinical Trial Participants
8. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
9. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
10. Sun Pharmaceutical Industries, Inc. Issues Nationwide Voluntary Recall of One Lot of Nimodipine Capsules due to Crystallization of the Fill Material
11. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):